GSTM1 and cholelithiasis: The analysis identified dose intensity (P=0.020), history of cholelithiasis (P=0.037), ALT (P=0.035), AST (P=0.016), and Hb (P=0.001) as independent risk factors for the incidence of HFS (Table 8).